Navigation Links
Par Pharmaceutical Reports Fourth Quarter and Full Year 2007 Results
Date:2/29/2008

ar ended December 31, 2006, to $77.7 million, and represented 10.1% of total revenues. The increase was due primarily to costs associated with the in-license of three Phase III products in support of the Company's branded division, Strativa. In June, the Company paid $3.0 million to Immtech Pharmaceuticals for the US commercialization rights to parfuramidine maleate. In July, the Company paid $15.0 million to BioAlliance Pharma for the US commercialization rights to Loramyc. In August, the Company acquired the North American commercial rights from Hana Biosciences, Inc. ("HANA") for Zensana(TM), at which time the Company made a $5.0 million equity investment in Hana at a contractually agreed premium. Of this amount, $1.2 million representing the premium paid was charged to R&D expense. In support of the Company's generic business, Par made a $5.0 million equity investment in IntelliPharmaCeutics Ltd., a privately held corporation, to develop and market four controlled release generic drug products. Of this amount, approximately $2.5 million, representing the premium paid, was charged to R&D.

Selling, general and administrative (SG&A) expense for the year ended December 31, 2007 decreased 6.9% to $138.2 million. The decrease in 2007 SG&A expense was primarily due to the non-recurrence of the second quarter 2006 write-off of approximately $10 million in bad debt for invalid customer deductions that the Company determined would not be pursued for collection, lower net severance costs, partially offset by the expansion of finance and accounting functions, higher other compensation related costs, including costs associated with the fourth quarter 2007 tender offer to repurchase certain unvested stock options, and increased professional costs related to the Company's restatement of prior periods.

Fourth Quarter 2007 Review

Total revenues of $155.1 million for the fourth quarter ended December 31, 2007, decreased 15.5% compared with the same period in
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Nastech Pharmaceutical Company Inc. to Hold Conference Call to Discuss Corporate Restructuring and Future Strategy on Monday, March 3, 2008
2. China Sky One Medical, Inc. to Acquire Heilongjiang Tianlong Pharmaceutical, Inc.
3. MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results
4. KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
5. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
6. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
7. VIA Pharmaceuticals to Present at Susquehanna and Rodman & Renshaw Conferences on March 4, 2008
8. Lotus Pharmaceuticals Raises $5 Million in Private Placement
9. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
10. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
11. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... HealthDay Reporter FRIDAY, Aug. 29, ... to two American aid workers successfully cured a group of ... report. The drug, ZMapp, prompted recovery in all 18 ... medication until five days after infection. ZMapp even cured ... even hours away from death, said study senior author Gary ...
(Date:9/1/2014)... Monday 1 September 2014: Permanent atrial fibrillation (AF) ... according to research in more than 6 000 patients ... from Belgium. The findings suggest that a simple clinical ... to better estimate stroke risk. , Ischaemic stroke is ... for over a million deaths and many more disabled ...
(Date:9/1/2014)... The National Association of Hispanic Nurses ( ... DNP, MPH, RN, and Adriana Perez, PhD, Rn, ANP-BC, ... Nursing. They will be inducted with Immediate Past President ... we reported last May. , Our three members will ... American Academy of Nursing Policy Conference in Washington, DC. ...
(Date:9/1/2014)... New York (PRWEB) September 01, 2014 ... store, retrieve, organize and analyze biological and genetic ... of the activity of developing software tools to ... not to be confused with biological computation. While ... better understanding of biology can its related concepts, ...
(Date:9/1/2014)... Parties involved in federally-filed Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ... in September, where issues related to claims involving the ... of Pennsylvania, Bernstein Liebhard LLP reports. , According ... Court’s website, the meeting is scheduled to take place ... the latest of several Tylenol conferences that have taken ...
Breaking Medicine News(10 mins):Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4
... you,re ready to drive again , , WEDNESDAY, Dec. 10 (HealthDay ... wheel again after orthopedic surgery or injury, but knowing when it,s ... , Orthopedic surgeons weigh in on the issue in the December ... , "Deciding when a patient can return to driving is ...
... (OTC Pink Sheets: SNDY ) is pleased to announce that ... by over 10% compared to the same time period for 2007. ... $28,509 for the same month last year. This marks the second ... of October. , , The Mammo ...
... Inc., a leading,provider of software and databases for systems ... Singapore Immunology Network (SIgN) has become a,certified GeneGo Center ... MetaCore, training and advanced support. SIgN COE will ... "We are excited ...
... Facilities , , NEW ... process, a proven commitment to clinical quality earned SigmaCare(R) ... Metropolitan Jewish Health System,s (Metropolitan) skilled nursing facilities. ... nationally recognized nonprofit organization, operates Metropolitan Jewish Geriatric Center, ...
... Pharma Services, Goodwill, , , ... NYSE: MDZ ), a leading provider of products and ... fiscal 2008 performance. , Based on preliminary information, MDS ... of $1,210 million to $1,220 million and adjusted EBITDA in the ...
... Care Insurance While They,re Still Healthy Enough to Qualify , ... If you,ve put off getting long term care insurance, ... new administration,s health plan? "I wouldn,t advise it," says Denise ... (LTCFP), one of the nation,s most experienced long term care ...
Cached Medicine News:Health News:Returning to the Road Tricky After Injury 2Health News:Solos Endoscopy, Inc. Increases Sales Revenue for October 2008 by Over 10% as Compared to Last Year 2Health News:A*STAR's Singapore Immunology Network Is the First GeneGo Center of Excellence in Asia 2Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 2Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 3Health News:MDS Provides Update on Fiscal 2008 Performance 2Health News:MDS Provides Update on Fiscal 2008 Performance 3Health News:MDS Provides Update on Fiscal 2008 Performance 4Health News:Obama Health Plan Not Likely to Embrace Long Term Care, Industry Leader Says 2
(Date:8/29/2014)... 2014  A Boston Scientific Corporation (NYSE: ... removability and preliminary long term stricture resolution of ... August issue of the peer-reviewed journal, Gastroenterology. ... being conducted in 11 countries and five continents, ... stents (FCSEMS) after extended indwell (i.e., up to ...
(Date:8/29/2014)... Medina Medical announced today that Mr. Engelson ... Board of Directors on August 18, 2014. Mr. Engelson ... experience, including over a decade of direct experience in ... Partner of the medical device incubator The Foundry, after ... start-ups. Mr. Engelson previously served as the Chief Financial ...
(Date:8/29/2014)... Aug. 29, 2014  BC Technical, the nation,s leading ... Medical Imaging, a leader in sales, service and installation ... allows BC Technical to continue to expand their resources ... and CT modalities. "We are committed ... Mark Alvarez , president and CEO of BC Technical. ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2BC Technical Acquires Polaris Medical Imaging 2
... PDL BioPharma, Inc. (PDL, the Company) (NASDAQ: PDLI ... aggregate principal amount of its 3.75% Convertible Senior Notes due ... conversion rate will initially be 126.2985 shares of common stock ... conversion price of approximately $7.92 per share of common stock. ...
... May 10, 2011 Cardica, Inc. (Nasdaq: CRDC ... and nine months ended March 31, 2011. Cardica,s management will ... to discuss the financial results and provide an update on ... diligently to bring our first anticipated commercial microcutter device, the ...
Cached Medicine Technology:PDL BioPharma, Inc. Prices Offering of $135.0 Million of Convertible Senior Notes Due 2015 2PDL BioPharma, Inc. Prices Offering of $135.0 Million of Convertible Senior Notes Due 2015 3PDL BioPharma, Inc. Prices Offering of $135.0 Million of Convertible Senior Notes Due 2015 4Cardica Announces Fiscal 2011 Third Quarter Financial Results 2Cardica Announces Fiscal 2011 Third Quarter Financial Results 3Cardica Announces Fiscal 2011 Third Quarter Financial Results 4Cardica Announces Fiscal 2011 Third Quarter Financial Results 5Cardica Announces Fiscal 2011 Third Quarter Financial Results 6
... OMNIPAQUE is an X-ray contrast ... and children for: angiography, urography, ... computed tomography of the basal ... endoscopic retrograde cholangio (pancreato) graphy ...
... IMAGOPAQUE is a non-ionic monomeric contrast ... in adults and children. After a decade ... 3.5 million examinations, IMAGOPAQUE has proven to ... effort in hundreds of radiology departments.Results from ...
... The only MR contrast agent FDA-approved ... is a gadolinium based, IV contrast media ... and liver. OptiMARK has convenient packaging ... contrast, packaged for efficient, problem-free delivery. You ...
... a contrast medium for Magnetic Resonance Imaging ... apyrogenic solution for intravenous injection. In MRI, ... brain, spine and surrounding tissues resulting in ... lesions with abnormal vascularity or those thought ...
Medicine Products: